Patient Groups Funded by Drugmakers Are Largely Mum on High Drug Prices

Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School shares his thoughts about pharmaceutical companies providing funding for patient groups while stifling the groups’ voice in the debate over increasing drug prices.

・ From USA Today